Published today. Thirty six PubMed records were found by our Chief Scientific Director Dr. Korobko to be relevant and of interest, and were included into this quarterly overview. The review includes sections on epidemiology, comorbidities, quality of life, vitiligo triggers, new case reports, new clinical studies and trials, analysis of mechanisms of vitiligo pathogenesis, genetic studies, candidate biomarkers, mechanisms of treatments, methodological advancements and novel treatment modalities.
- Which diseases most commonly accompany vitiligo?
According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...
- Is it Bitiligo? Vitaligo? Veteligo?
There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...
- Shall I take vitamin D for my vitiligo?
In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.